Brazil Drug Delivery Devices Market Size
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2021 - 2022 |
| CAGR | 4.50 % |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Brazil Drug Delivery Devices Market Analysis
The Brazil drug delivery devices market is expected to register a CAGR of 4.5% over the forecast period.
COVID-19 had a significant impact on the Brazil drug delivery devices market in early 2020 owing to the factors such as country-wide lockdowns leading to less export and import of drug delivery devices. For instance, according to the article published in May 2021 in PubMed, Cruz Foundation (Fiocruz) revealed that the prevalence of acute respiratory distress syndrome (ARDS) in Brazil significantly increased during the pandemic, which was likely explained by several COVID-19 cases being diagnosed as acute respiratory distress syndrome (ARDS). Hence, most people utilize nebulizers and inhalers to alleviate breathing difficulty. As a result, the demand for drug delivery devices increased in Brazil. Furthermore, drug delivery devices export and import got delayed, making the situation challenging in the initial pandemic phases. However, the market is currently showing stable growth and is expected to follow the same over the next 3-4 years. Factors such as an increase in the number of chronic diseases and the rise in research and development activities are anticipated to boost the market growth in the coming years.
The high prevalence of chronic diseases is likely to increase the demand for drug-delivery devices, which is anticipated to boost the market growth. For instance, according to the IDF Diabetes Atlas 2021, 15,733,600 people were affected with diabetes in Brazil in 2021. The rising incidence of diabetes is likely to demand insulin drug delivery devices, expected to drive the drug delivery devices market in Brazil over the forecast period. Furthermore, the presence of competitors, mergers acquisition, and collaboration in the studied region is likely to increase the market growth as these improve the chances of product availability and competition. For instance, in February 2022, Eurofarma, a multinational pharmaceutical business with 100% Brazilian capital, introduced the generic medicine dexamethasone + thiamine hydrochloride + pyridoxine hydrochloride + cyanocobalamin, indicated for the treatment of inflammatory neuropathies. The medicine is available in pharmacies throughout Brazil as an injectable solution in packages of six ampoules. Hence, product launches relating to drug delivery devices like injectables will likely boost market growth over the forecast period.
Hence, due to the rise in the prevalence of chronic diseases and the high demand for drug delivery devices, Brazil's drug delivery devices market is expected to witness growth over the forecast period. However, the risk associated with needlestick injuries may restrain the market growth over the forecast period.
Brazil Drug Delivery Devices Market Trends
This section covers the major market trends shaping the Brazil Drug Delivery Devices Market according to our research experts:
Ocular Segment is Likely to Witness a Growth in the Brazil Drug Delivery Devices Market Over the Forecast Period
The ocular segment is expected to witness significant growth over the forecast period because of the high prevalence of ophthalmic diseases and increased research and drug discovery development. For instance, as per the article published in February 2021 by SciELO, Glaucoma is the primary cause of blindness and irreversible visual damage in Brazil. Furthermore, according to the study published in November 2021 in PubMed, dry eye symptoms were found to be a prevalent condition among Brazilian university students compared to the rate of dry eye among the general Brazilian population over 40 years of age. Hence, as the number of eye disease cases rises, the demand for look drops, ocular inserts, and other ophthalmic drug delivery devices increases, thereby boosting market growth over the forecast period. Additionally, according to the study published in March 2022 in PubMed, dry eye disease prevalence in Sao Paulo was higher in women than in men. It also stated that age and hypertension were more potent risk factors for dry eye disease in women. Therefore, increasing cases of eye disorders are anticipated to propel the market growth over the forecast period.
Moreover, the increase in product launches, mergers, acquisitions, collaboration, research, and development in the field of the ocular segment is anticipated to boost the market growth over the forecast period. For instance, in September 2021, the Federal University of Rio Grande do Sul sponsored a clinical trial to compare the efficacy of PSLT and the topical use of prostaglandin-like hypotensive eye drops in the treatment of ocular hypertensive or glaucomatous patients in decreasing intraocular pressure and measuring changes in functional, structural and biomechanical parameters evaluated by computerized perimetry and optical coherence tomography (OCT) related to pressure change resulting from treatments.
Additionally, the increase in diabetes cases in Brazil is likely to drive the significant risk of developing diabetic retinopathy in patients, which is projected to increase the demand for drug-delivery devices in the ocular segment, thereby boosting market growth over the forecast period.
Hence, considering the rise in the number of eye diseases and research and development associated with ocular drug delivery devices, the visual segment is expected to witness significant growth in the Brazilian drug delivery market over the forecast period.
Infectious Diseases Segment is Anticipated to Witness a Growth in the Brazil Drug Delivery Devices Market Over the Forecast Period
Infectious diseases are disorders caused by organisms such as bacteria, viruses, fungi, or parasites. Immunization can prevent the suffering associated with infectious diseases like polio, measles, and pneumonia. For that purpose, syringes or prefilled syringes are widely used as drug delivery devices. The infectious disease segment is likely to witness growth in the Brazil drug delivery devices market owing to the factors such as a rise in infectious diseases, demand for vaccinations, and an increase in healthcare expenditure. For instance, as per the PAHO 2022 update, the number of Zika cases in Brazil was 29,117 cases ( 92.6 %) in 2022. As per the same source, As of epidemiological week (EW) 40 of 2022, the highest number of chikungunya cases have been reported by Brazil, with 247,537 cases, which represents (98.9 %) of total regional cases. Hence, the rise in the number of infectious diseases leads to an increase in demand for drug-delivery devices like syringes, which is anticipated to boost market growth over the forecast period.
Furthermore, research and development studies of infectious diseases are anticipated to boost market growth over the forecast period. For instance, in January 2022, Instituto Butantan, Brazil sponsored a study, which is to evaluate the immunogenicity and safety of the adult dose of VLA1553 (chikungunya vaccine) 28 days following the single immunization. Immunogenicity evaluations in the immunogenicity subset will include the proportion of subjects with seroprotective neutralizing CHIKV antibody titers above a surrogate threshold indicative of protection. Additionally, Sanofi conducted a clinical study in Brazil location in March 2022, to evaluate the safety of the dengue vaccine in pregnant women and their offspring. Hence, for such studies, the utilization of drug delivery devices like prefilled syringes is widely used, which is anticipated to drive market growth over the forecast period.
Additionally, with proper immunization, infectious diseases including diphtheria, pertussis, measles, and polio can be treated. It is frequently accomplished through widespread immunization campaigns or hospital-sponsored vaccination drives. According to the PAHO's 2022 vaccine coverage report, 73.46% of MMR1 (the measles, mumps, and rubella vaccine) vaccinations were carried out in Brazil. As the vaccination increases, the demand for drug delivery devices like prefilled syringes is anticipated to increase thereby driving the market growth in Brazil.
Hence, considering the rise in infectious diseases, the increase in research and development in infectious diseases, and the demand for drug delivery devices in vaccination, the infectious disease segment is anticipated to witness growth in the Brazil drug delivery devices market over the forecast period.
Brazil Drug Delivery Devices Industry Overview
The Brazil drug delivery devices market is fragmented due to the presence of several companies operating globally and regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Major key players include Sanofi, GSK plc, Pfizer Inc., Eurofarma and Becton, Dickinson, and Company among others.
Brazil Drug Delivery Devices Market Leaders
-
Sanofi
-
GSK plc
-
Pfizer Inc.
-
Novartis AG
-
Eurofarma
*Disclaimer: Major Players sorted in no particular order
Brazil Drug Delivery Devices Market News
- In September 2022, Evandro Chagas National Institute of Infectious Disease sponsored a clinical trial study under the title "The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir (ImPrepCab)" the study is to assess the safety and effectiveness of open-label CAB LA PrEP when offered at public health facilities to cisgender men and transgender or gender non-binary individuals. Cabotegravir (CAB-LA) is given as injectable.
- In June 2021, a clinical trial was sponsored by Instituto Nacional de Cancer, Brazil, under the title "Evaluation of Intravenous Lidocaine and Time to Regression of the Sensory Block After Spinal Anesthesia (ELSA Trial) (ELSA)", the Phase III study assessed to confirm that SNG001 can accelerate the recovery of hospitalized patients receiving oxygen with confirmed Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). The Lidocaine was given as an infusion through an infusion pump.
Brazil Drug Delivery Devices Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Chronic Diseases
- 4.2.2 Increased Funding and Research Activity in Drug Development
-
4.3 Market Restraints
- 4.3.1 Risk Associated With Needlestick Injuries
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
-
5.1 By Route of Administration
- 5.1.1 Injectable
- 5.1.2 Topical
- 5.1.3 Ocular
- 5.1.4 Other Route of Administration
-
5.2 By Application
- 5.2.1 Cancer
- 5.2.2 Cardiovascular
- 5.2.3 Diabetes
- 5.2.4 Infectious diseases
- 5.2.5 Other Applications
-
5.3 By End User
- 5.3.1 Hospitals
- 5.3.2 Ambulatory Surgical Centers
- 5.3.3 Other End Users
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Pfizer Inc.
- 6.1.2 Novartis AG
- 6.1.3 Johnson and Johnson
- 6.1.4 Becton, Dickinson and Company
- 6.1.5 Sanofi
- 6.1.6 GSK plc
- 6.1.7 Teva Pharmaceutical Industries Ltd
- 6.1.8 Eurofarma
- 6.1.9 Merck KGaA
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityBrazil Drug Delivery Devices Industry Segmentation
As per the scope of the report, drug delivery devices or systems are the tools used to deliver the drug through the specific route of administration. It enables the introduction of therapeutic substances into the body. The Brazil Drug Delivery Devices Market is Segmented by Route of Administration (Injectable, Topical, Ocular, and Others), Application (Cancer, Cardiovascular, Diabetes, Infectious Diseases, and Other Applications), End User (Hospitals, Ambulatory Surgical Centers, and Other End Users). The report offers the value (in USD million) for the above segments.
| By Route of Administration | Injectable |
| Topical | |
| Ocular | |
| Other Route of Administration | |
| By Application | Cancer |
| Cardiovascular | |
| Diabetes | |
| Infectious diseases | |
| Other Applications | |
| By End User | Hospitals |
| Ambulatory Surgical Centers | |
| Other End Users |
Brazil Drug Delivery Devices Market Research FAQs
What is the current Brazil Drug Delivery Devices Market size?
The Brazil Drug Delivery Devices Market is projected to register a CAGR of 4.5% during the forecast period (2024-2029)
Who are the key players in Brazil Drug Delivery Devices Market?
Sanofi, GSK plc, Pfizer Inc., Novartis AG and Eurofarma are the major companies operating in the Brazil Drug Delivery Devices Market.
What years does this Brazil Drug Delivery Devices Market cover?
The report covers the Brazil Drug Delivery Devices Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Brazil Drug Delivery Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Asia-Pacific Medical Aesthetic Devices Industry Report
Statistics for the 2024 Asia-Pacific Medical Aesthetic Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Asia-Pacific Medical Aesthetic Devices analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
